Lyndra Therapeutics Collaborates with Thermo Fisher for New Therapies

Lyndra Therapeutics and Thermo Fisher Scientific Partnership

Lyndra Therapeutics, a pioneering clinical-stage biopharmaceutical company known for innovative long-acting oral therapies, has recently entered a strategic collaboration with Thermo Fisher Scientific Inc., a global leader offering scientific services. This partnership aims to enhance the development and manufacturing of Lyndra's long-acting oral therapies.

Details of the Collaboration

The collaboration allows Lyndra to leverage Thermo Fisher's extensive capabilities in global clinical research and commercial manufacturing. Their alliance signifies a step forward in delivering Lyndra's pioneering drug delivery systems, including their lead investigational product, oral weekly risperidone (LYN-005). This innovative therapy is designed to provide effective medication from a single oral dose for an entire week or longer.

Recent Breakthroughs in Research

LYN-005 has already shown promising results, successfully meeting its primary endpoint in the key phase 3 STARLYNG-1 study, which compared it with daily injections of Risperdal. Excitingly, Lyndra is preparing to initiate another crucial safety study of the oral weekly risperidone, projected to begin within the upcoming year.

Advancing Drug Delivery Systems

According to Dr. Richard Scranton, President of Global Product Development at Lyndra Therapeutics, this partnership with Thermo Fisher is pivotal in their mission to revolutionize how medications are consumed. He emphasizes that with Thermo Fisher's support, Lyndra can concentrate on its core competency of research and development, while also relying on Thermo Fisher’s reliable manufacturing and clinical trial operations.

Utilizing Thermo Fisher’s Cutting-Edge Services

Among the various resources available through this collaboration are Thermo Fisher's Accelerator™ Drug Development services. These services encompass a comprehensive suite tailored to both emerging biotech companies and established pharmaceutical players, facilitating the various stages from initial research to full-scale commercialization.

Manufacturing Capabilities and Achievements

Lyndra plans to utilize Thermo Fisher’s advanced pharmaceutical manufacturing facilities, notably in Cincinnati, Ohio. Here, they will focus on producing commercial materials in large quantities, specifically leveraging Lyndra’s innovative LYNX drug delivery technology.

Future Implications for the Pharmaceutical Industry

This collaboration also presents opportunities for pharmaceutical companies interested in using Lyndra’s LYNX platform technology to create their own long-acting oral therapies. By working with Thermo Fisher, these partners can accelerate their development processes and streamline their pathways to market.

Understanding the LYNX Drug Delivery Platform

The LYNX drug delivery platform aims to enhance clinical outcomes by refining how oral medications are administered and consumed. Enabling stable and sustained delivery of medicines in a targeted therapeutic window, the technology produces effective outcomes from a single oral administration over an extended period. The invention draws on over fifty patented advancements in design, engineering, and material science.

About Lyndra Therapeutics

Lyndra Therapeutics is dedicated to transforming the pharmaceutical landscape with their LYNX platform. By facilitating less frequent dosing while maintaining stable drug exposure, they aim to significantly improve patient experiences. With clinical proof-of-concept established across various therapeutic areas and multiple active pharmaceutical ingredients (APIs), Lyndra is poised to redefine the paradigm of oral medication delivery in health care.

Frequently Asked Questions

What is the focus of the collaboration between Lyndra Therapeutics and Thermo Fisher Scientific?

The collaboration focuses on providing clinical research and commercial manufacturing services to enhance the development of long-acting oral therapies by Lyndra Therapeutics.

What is LYN-005, and what are its recent achievements?

LYN-005 is Lyndra's lead investigational product, an oral weekly risperidone that has met its primary endpoint in phase 3 pivotal studies, demonstrating its efficacy compared to daily medications.

How does the partnership benefit the pharmaceutical industry?

By connecting Lyndra’s LYNX platform with Thermo Fisher’s extensive manufacturing services, the collaboration accelerates the development timelines for other pharmaceutical companies interested in creating long-acting oral therapies.

What are the goals of the LYNX drug delivery platform?

The LYNX platform aims to optimize oral medication delivery, providing long-lasting effects with fewer doses, thereby enhancing patient adherence and overall treatment outcomes.

Where is Thermo Fisher’s manufacturing facility located that will be utilized for this collaboration?

Lyndra plans to leverage Thermo Fisher's manufacturing capabilities located in Cincinnati, Ohio, for commercial scale production.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.